Section 2: Selection, Procurement and Distribution

2SPD-020

DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS

2SPD-019

TOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES

2SPD-018

IMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA

2SPD-017

RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS

2SPD-016

DATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS

2SPD-015

INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE

2SPD-014

ECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS

2SPD-013

A COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION

2SPD-012

APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS' DRUG STOCK MANAGEMENT PROCESSES

2SPD-011

AVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION

2SPD-010

IDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT

2SPD-009

A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION

2SPD-008

SWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD!

2SPD-007

USE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL

2SPD-006

IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022)

Pages